Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review

被引：35

作者：

Nseir, William ^{[1
]}

Mahamid, Mahmud ^{[2
]}

机构：

[1] Bar Ilan Univ, Fac Med Galilee, Holy Family Hosp, Dept Internal Med, IL-16100 Safed Israel, Nazareth, Israel

[2] Holy Family Hosp, Dept Internal Med, Nazareth, Israel

来源：

CURRENT ATHEROSCLEROSIS REPORTS | 2013年 / 15卷 / 03期

关键词：

Fatty liver; Steatohepatitis; Statins; Hyperlipidemia; Metabolic syndrome; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED-TRIAL; METABOLIC SYNDROME; HYPERLIPIDEMIC PATIENTS; INSULIN-RESISTANCE; OPEN-LABEL; LONG-TERM; EFFICACY; ATORVASTATIN; SIMVASTATIN;

D O I：

10.1007/s11883-012-0305-5

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease that refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD is an asymptomatic disease that can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The most common cause of mortality in patients with NAFLD or NASH is cardiovascular disease (CVD). Currently, the treatment of NAFLD focuses on gradual weight loss and life style modifications. However, multifactorial treatment of NAFLD or NASH risk factors may be needed to reduce the likelihood of these patients developing CVD. This review discusses the mechanisms that link hyperlipidemia and NAFLD. In addition, the review focuses on the safety and efficacy of statins in patients with NAFLD or NASH, and their effect on the extent of hepatic steatosis and fibrosis based on human studies.

引用

页数：6

共 46 条

[11] Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].

Bugianesi, E ;

Leone, N ;

Vanni, E ;

Marchesini, G ;

Brunello, F ;

Carucci, P ;

Musso, A ;

De Paolis, P ;

Capussotti, L ;

Salizzoni, M ;

Rizzetto, M .

GASTROENTEROLOGY, 2002, 123 (01) :134-140

[12] Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity [J].

Chalasani, N ;

Aljadhey, H ;

Kesterson, J ;

Murray, MD ;

Hall, SD .

GASTROENTEROLOGY, 2004, 126 (05) :1287-1292

[13] Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization [J].

Charles, EC ;

Olson, KL ;

Sandhoff, BG ;

McClure, DL ;

Merenich, JA .

AMERICAN JOURNAL OF MEDICINE, 2005, 118 (06) :618-624

[14] Apolipoprotein synthesis in nonalcoholic steatohepatitis [J].

Charlton, N ;

Sreekumar, R ;

Rasmussen, D ;

Lindor, K ;

Nair, KS .

HEPATOLOGY, 2002, 35 (04) :898-904

[15]

Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3

[16] Steatohepatitis: A tale of two "hits"? [J].

Day, CP ;

James, OFW .

GASTROENTEROLOGY, 1998, 114 (04) :842-845

[17] Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial [J].

Foster, Temitope ;

Budoff, Matthew J. ;

Saab, Sammy ;

Ahmadi, Naser ;

Gordon, Craig ;

Guerci, Alan D. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (01) :71-77

[18]

Georgescu EF, 2007, J GASTROINTEST LIVER, V16, P39

[19]

Ginsberg HN, 2000, J CARDIOVASC RISK, V7, P325

[20] A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients [J].

Gomez-Dominguez, E. ;

Gisbert, J. . P. ;

Moreno-Monteagudo, J. A. ;

Garcia-Buey, L. ;

Moreno-Otero, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (11) :1643-1647

← 1 2 3 4 5 →